Long Shortz with Race Oncology: collaboration with Monash University
Stockhead TV
share
Stockhead’s Fraser Palamara sits down with Race Oncology’s (ASX:RAC) CEO Dr Daniel Tillett to get the short end of the long story on the company’s latest news.
The biopharmaceutical company has successfully completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform.
There is significant scientific and pharmaceutical industry interest in developing FTO inhibitor drugs as potential new cancer treatments.
Tune in to hear Race Oncology’s Dr Daniel Tillett on why this is a significant result and what to expect next for Race Oncology.
This video was developed in collaboration with Race Oncology, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
